Literature DB >> 20212081

Heart failure and mouse models.

Ross Breckenridge1.   

Abstract

Heart failure is a common, complex condition with a poor prognosis and increasing incidence. The syndrome of heart failure comprises changes in electrophysiology, contraction and energy metabolism. This complexity, and the interaction of the clinical syndrome with very frequently concurrent medical conditions such as diabetes, means that animal modelling of heart failure is difficult. The current animal models of heart failure in common use do not address several important clinical problems. There have been major recent advances in the understanding of cardiac biology in the healthy and failing myocardium, but these are, as yet, unmatched by advances in therapeutics. Arguably, the development of new animal models of heart failure, or at least adaptation of existing models, will be necessary to fully translate scientific advances in this area into new drugs. This review outlines the mouse models of heart failure in common usage today, and discusses how adaptations in these models may allow easier translation of animal experimentation into the clinical arena.

Entities:  

Mesh:

Year:  2010        PMID: 20212081     DOI: 10.1242/dmm.005017

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN: 1754-8403            Impact factor:   5.758


  35 in total

1.  Cardiospecific deletion of αE-catenin leads to heart failure and lethality in mice.

Authors:  Volodymyr V Balatskyi; Larysa L Macewicz; Ana-Maria Gan; Sergii V Goncharov; Paulina Pawelec; Georgiy V Portnichenko; Tetiana Yu Lapikova-Bryginska; Viktor O Navrulin; Victor E Dosenko; Adam Olichwier; Pawel Dobrzyn; Oksana O Piven
Journal:  Pflugers Arch       Date:  2018-06-20       Impact factor: 3.657

2.  A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats.

Authors:  Hui-Chun Ku; Shih-Yi Lee; Yuan-Kun Aden Wu; Kai-Chien Yang; Ming-Jai Su
Journal:  J Vis Exp       Date:  2016-12-02       Impact factor: 1.355

3.  IRX1 hypermethylation promotes heart failure by inhibiting CXCL14 expression.

Authors:  Longhuan Zeng; Nanyuan Gu; Jiayi Chen; Guangyong Jin; Yongke Zheng
Journal:  Cell Cycle       Date:  2019-10-22       Impact factor: 4.534

4.  Guidelines for translational research in heart failure.

Authors:  Enrique Lara-Pezzi; Philippe Menasché; Jean-Hugues Trouvin; Lina Badimón; John P A Ioannidis; Joseph C Wu; Joseph A Hill; Walter J Koch; Albert F De Felice; Peter de Waele; Valérie Steenwinckel; Roger J Hajjar; Andreas M Zeiher
Journal:  J Cardiovasc Transl Res       Date:  2015-01-21       Impact factor: 4.132

Review 5.  Genetics of common forms of heart failure: challenges and potential solutions.

Authors:  Christoph D Rau; Aldons J Lusis; Yibin Wang
Journal:  Curr Opin Cardiol       Date:  2015-05       Impact factor: 2.161

6.  Mapping genetic contributions to cardiac pathology induced by Beta-adrenergic stimulation in mice.

Authors:  Christoph D Rau; Jessica Wang; Rozeta Avetisyan; Milagros C Romay; Lisa Martin; Shuxun Ren; Yibin Wang; Aldons J Lusis
Journal:  Circ Cardiovasc Genet       Date:  2014-12-05

7.  Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study.

Authors:  Christi T Salisbury-Ruf; Clinton C Bertram; Aurelia Vergeade; Daniel S Lark; Qiong Shi; Marlene L Heberling; Niki L Fortune; G Donald Okoye; W Gray Jerome; Quinn S Wells; Josh Fessel; Javid Moslehi; Heidi Chen; L Jackson Roberts; Olivier Boutaud; Eric R Gamazon; Sandra S Zinkel
Journal:  Elife       Date:  2018-10-03       Impact factor: 8.140

8.  Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection.

Authors:  Xianli Wang; Qian Wang; Wei Guo; Yi Zhun Zhu
Journal:  Biosci Rep       Date:  2011-04       Impact factor: 3.840

9.  Comparison of 4D-microSPECT and microCT for murine cardiac function.

Authors:  Nicholas T Befera; Cristian T Badea; G Allan Johnson
Journal:  Mol Imaging Biol       Date:  2014-04       Impact factor: 3.488

10.  Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension.

Authors:  Germán E González; Nour-Eddine Rhaleb; Martin A D'Ambrosio; Pablo Nakagawa; Yunhe Liu; Pablo Leung; Xiangguo Dai; Xiao-Ping Yang; Edward L Peterson; Oscar A Carretero
Journal:  J Hypertens       Date:  2015-01       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.